Fluralaner (Bravecto) for Canine Generalized Demodicosis: Field Study Evidence

Bottom line

• As of July 2026, a single administration of fluralaner (Bravecto) achieves 98.0% mite-free rates in generalized canine demodicosis across both the oral chewable and spot-on formulations in a 134-dog European multicenter field study — both forms outperforming imidacloprid/moxidectin, which failed the 90% efficacy threshold at 87.5% mite-free.[1]
• In a controlled laboratory study, a single topical fluralaner application eliminated Demodex mites at 99.7% by Day 28, exceeding 99.9% by Day 56 and reaching 100% by Day 84 — versus 9.8%, 45.4%, and 0% for topical imidacloprid/moxidectin given three or more times.[2]
• The same molecule's acaricidal reach now extends beyond Demodex: a 2026 blinded RCT cured naturally acquired sarcoptic mange with a single fluralaner dose (100% by Day 28), and an oral afoxolaner-moxidectin-pyrantel combination cleared Sarcoptes scabiei in a field trial (97% after one dose, 100% after two) — reinforcing single-dose convenience as a class advantage while the head-to-head ranking between isoxazolines is still being defined.[3][5]
• Fluralaner belongs to the isoxazoline class, which carries an FDA label warning for neurologic adverse reactions (tremors, ataxia, seizures). 2025–2026 reviews reaffirm wide safety margins but flag a rare, sometimes serious neurologic signal concentrated in dogs with impaired drug efflux (ABCB1/MDR1 variants or P-glycoprotein inhibition) — take a medication and breed history before treating and reassess promptly if neurologic signs appear.[6][7]
• Efficacy against mites should not be over-extrapolated: a 2025 PRISMA systematic review confirms broad acaricidal activity but a hard limit — fluralaner does not prevent bites or blood-borne pathogen transfer, because it kills after attachment rather than repelling.[7]
• In the US, the oral chewable is FDA-approved for fleas and ticks only (NADA 141-426); demodicosis use with the oral chew is off-label, while the topical spot-on carries EMA authorization that includes generalized demodicosis.

Drug facts

• Class: Isoxazoline ectoparasiticide (class members: fluralaner, afoxolaner, sarolaner, lotilaner)
• Mechanism of action: Potent inhibitor of GABA-gated and glutamate-gated chloride channels in invertebrates; high selectivity for arthropod over mammalian receptors underlies the safety margin. It is acaricidal/insecticidal after the parasite attaches and feeds — it is not a repellent.[7]
• Route/interval: Oral chewable tablet or topical spot-on. A single administration is used for demodicosis and for the sarcoptic/otodectic mange indication (distinct from the every-12-weeks dosing interval used for flea/tick prevention).[1][3]
• Pharmacokinetics: Long tissue half-life (9.3–16.2 days following oral administration) sustains miticidal concentrations well beyond the initial dose; these lipophilic compounds accumulate in tissue, which is the basis of single-dose efficacy but also raises questions about delayed effects and (per systematic review) extended fecal excretion / environmental contamination.[2][7]
• Indication: Generalized canine demodicosis (off-label for the US oral chewable; EMA-authorized for the topical spot-on). Broader isoxazoline evidence supports sarcoptic and otodectic mange.[1][3]
• Approval: FDA NADA 141-426 (US, oral/chewable, flea/tick); EMA authorization includes demodicosis for the topical spot-on formulation.
• Label contraindications/precautions: Use with caution in dogs with a history of seizures or neurologic disorders. Heightened caution in dogs with known or suspected ABCB1/MDR1 variants or concurrent P-glycoprotein inhibitors.[6]
• Label common AEs: Vomiting, decreased appetite, diarrhea, lethargy, hypersalivation; class-level warning for tremors, ataxia, and seizures.

Efficacy for generalized demodicosis

Controlled laboratory comparison: spot-on formulations

Fourie et al. (2019, Parasites & Vectors) enrolled 16 client-owned dogs with naturally acquired generalized demodicosis in a randomized controlled laboratory study. Dogs were allocated to either a single topical application of fluralaner spot-on (Day 0 only) or three applications of topical imidacloprid/moxidectin on Days 0, 28, and 56 (weekly in severe cases). Mite burden was quantified from five deep skin-scraping sites per dog at 28-day intervals over 12 weeks.[2]

By Day 28, the fluralaner group achieved 99.7% miticidal efficacy; by Day 56, greater than 99.9%; and by Day 84, 100%. The imidacloprid/moxidectin group reached only 9.8% at Day 28, 45.4% at Day 56, and 0% at Day 84, with statistically significant differences at all post-treatment time points (P < 0.01). The complete loss of efficacy in the comparator arm at Day 84 despite three or more treatments underscores the pharmacokinetic advantage of fluralaner: its long tissue half-life (9.3–16.2 days) sustains miticidal concentrations well past a single dose.[2]

Multicenter European field study: oral and topical formulations compared

Petersen et al. (2020, Parasites & Vectors) conducted a larger randomized field assessment across veterinary clinics in five European countries, enrolling 134 dogs with naturally acquired generalized demodicosis (124 completers). Dogs were allocated 2:2:1 to fluralaner oral chewable (single dose), fluralaner spot-on (single dose), or topical imidacloprid/moxidectin per label (three applications at 28-day intervals). The prespecified efficacy threshold was greater than 90% mite-free at Days 56 and 84.[1]

Both fluralaner formulations met the threshold: 98.0% mite-free for oral and 98.0% for spot-on. The comparator did not: 87.5% mite-free overall, falling below the threshold. The 2:2:1 design provides a direct within-study comparison of oral versus topical fluralaner, and the two routes achieved equivalent results — offering practical flexibility when one route is preferable. Skin lesions improved markedly by Day 28 in the fluralaner groups, well ahead of full mite clearance, and no treatment-related adverse events were recorded.[1]

Comparators and how fluralaner ranks

The two demodicosis studies above position fluralaner well ahead of topical imidacloprid/moxidectin for mite elimination. Against other isoxazolines, comparative data are still emerging and, where they exist, favor single-dose convenience without establishing a definitive efficacy hierarchy.

Fluralaner vs. sarolaner (sarcoptic mange). Cruz et al. (2026, Parasites & Vectors) ran two randomized, double-blind clinical studies in naturally infested dogs comparing a fluralaner palatable tablet with a sarolaner-based reference product. Against Sarcoptes scabiei, the fluralaner group reduced mite counts significantly from Day 14 (p = 0.022) and reached 100% efficacy by Day 28 without retreatment, whereas the sarolaner control reduced mites significantly from Day 7 (p = 0.045) but required retreatment to reach 100% by Day 44. Against Otodectes cynotis (ear mites), fluralaner reached 94.1% by Day 14 and 100% from Day 21, while the sarolaner control reached 100% by Day 14. The authors flag the small sample and call for further trials, so this is a single-dose convenience signal rather than a settled superiority claim.[3][4]

Isoxazolines as a class (systemic scabies treatment). A critically appraised topic (Dumitrache & Cadiergues, 2023, BMC Veterinary Research) concluded that afoxolaner, fluralaner, and sarolaner — alongside macrocyclic lactones — can all achieve parasitological and clinical cure of canine scabies, without ranking them against one another.[4]

Multimodal and combination options

Isoxazoline monotherapy is not the only oral route to cure for mite disease. Antoine et al. (2026, Parasite) reported a blinded, randomized, single-centre, negative-controlled field study of an oral afoxolaner-moxidectin-pyrantel pamoate combination in 20 dogs naturally infested with Sarcoptes scabiei. Treated dogs received the label dose on Day 0 and again on Day 26/28; mite infestations were reduced by 97% after the first treatment and eliminated (100%) after the second (p < 0.0005), while all untreated controls remained infested throughout. By Day 56, treated dogs had no pruritus, papules, or crusts and showed clear hair regrowth.[5]

The negative-controlled design strengthens attribution of cure to the treatment. For clinicians, the takeaway is that a combination product delivering a macrocyclic lactone plus an isoxazoline is a viable field-proven option for scabies, though it required two doses to reach 100% in this study versus the single-dose fluralaner result in the blinded RCT above — a convenience difference to weigh against formulary, endoparasite coverage, and cost considerations.[3][5]

Safety, adverse events, and the isoxazoline class warning

Since 2018, the FDA has required a class-wide label warning for isoxazoline ectoparasiticides — including fluralaner — regarding potential neurologic adverse reactions (tremors, ataxia, seizures), applied particularly to dogs with a history of seizures or neurologic disorders. Neither the Fourie 2019 nor the Petersen 2020 demodicosis study reported treatment-related adverse events, and the fluralaner chewable field study (NADA 141-426 supporting data, n = 294) confirmed a favorable safety profile.[1][2]

Two 2025–2026 reviews sharpen where the residual risk sits. A pharmacology and toxicology review (Markowska-Buńka et al., 2026, Int J Parasitol Drugs Drug Resist) concludes that controlled studies generally demonstrate wide safety margins for fluralaner, afoxolaner, sarolaner, and lotilaner, but that post-marketing pharmacovigilance has identified rare, sometimes serious neurologic adverse events — particularly in predisposed animals or in the context of impaired efflux transport such as ABCB1/MDR1 mutations or P-glycoprotein inhibition. The signal is mechanistically plausible: reduced P-glycoprotein function can raise central exposure to a drug whose arthropod-versus-mammalian receptor selectivity is otherwise protective.[6]

A 2025 systematic review of fluralaner across mammals (Jiang & Old, 2025, PeerJ) graded the drug as moderately safe; of the 19 studies that reported side effects, one included signs of severe neurological toxicity. Both reviews caution that much of the published safety data come from small studies of fair methodological quality, so absolute event rates remain uncertain even as the products perform well in controlled trials.[6][7]

A large owner-reported survey of canine isoxazoline use (Palmieri et al., 2020, Vet Med Sci) provides complementary real-world signal-gathering that controlled trials cannot capture, underscoring why pharmacovigilance remains important alongside registration studies.[8]

Neutral synthesis: the efficacy and tolerability picture for demodicosis remains favorable, and controlled trials continue to show wide safety margins. The countervailing evidence is not a contradiction of that efficacy but a refinement of case selection — the serious neurologic events are rare, cluster in dogs with impaired drug efflux, and are drawn from a safety base that is still limited in study quality and size.

Contraindications, precautions & PK

• Seizure/neurologic history: Use with caution; the FDA class warning applies most directly here. Discuss risk with the owner and heighten post-treatment monitoring.
• ABCB1/MDR1 status and P-glycoprotein inhibitors: The rare serious neurologic signal concentrates in dogs with impaired drug efflux. Take a medication and breed history before treatment; be alert to concurrent P-gp inhibitors that could raise central exposure.[6]
• Pharmacokinetics: Long tissue half-life (9.3–16.2 days after oral dosing) is the basis of single-dose efficacy; lipophilicity drives tissue accumulation. Extended fecal excretion has raised environmental-contamination questions in the systematic-review literature.[2][7]
• Scope limit (not a repellent): Fluralaner kills after attachment and does not prevent bites or blood-borne pathogen transfer — vector-borne-disease prevention depends on kill-speed and the local transmission window, not on this drug.[7]
• Concomitant ectoparasiticides / full label: Review the full NADA label (NADA 141-426) and any concurrent ectoparasiticides before use, especially in dogs with a seizure history.

Practical decision support

Generalized canine demodicosis has historically been managed with amitraz dips, daily oral ivermectin-class drugs (off-label), or topical imidacloprid/moxidectin — protocols requiring weeks of daily or frequent administration with meaningful tolerability challenges. The evidence reviewed here establishes a different pattern: a single administration of fluralaner, oral or topical, consistently achieves and sustains miticidal efficacy well past the 84-day endpoint.[1][2]

• Simplify the schedule. A single dose replaces multi-week daily administration for most cases, improving owner compliance and reducing cumulative isoxazoline exposure.[1]
• Route flexibility. Oral and topical fluralaner were statistically equivalent in the field study, so patients with barriers to oral administration (severe vomiting, liver disease, behavioral difficulty pilling) can be offered the spot-on without compromising efficacy expectations.[1]
• Adult-onset demodicosis. Both fluralaner forms performed well across juvenile- and adult-onset subtypes in the Petersen 2020 data (96.0–100% mite-free), which is notable for adult-onset disease — but adult-onset warrants investigation for underlying immunosuppression or systemic disease regardless of the acaricide chosen. Fluralaner addresses mite burden; it does not modify an underlying cause.[1]
• Screen before treating. Take a medication and breed history; where ABCB1/MDR1 status is unknown in a predisposed breed, weigh testing or heightened monitoring. Reassess promptly if neurologic signs appear.[6]
• Set expectations on scope. Excellent mite clearance does not equal vector-borne-disease prevention; counsel owners that this is an acaricide, not a repellent.[7]
• Beyond Demodex. For sarcoptic or otodectic mange, single-dose fluralaner and combination afoxolaner-moxidectin-pyrantel are both supported by 2026 controlled/field data; choose on the basis of endoparasite coverage needs, formulary, dose count, and cost.[3][5]

Frequently Asked Questions

Is fluralaner FDA-approved for canine generalized demodicosis in the US? The oral chewable (NADA 141-426) is FDA-approved in the US for flea and tick control only, so demodicosis use is off-label. The topical spot-on has EMA authorization in Europe that includes generalized demodicosis.

How does fluralaner compare to imidacloprid/moxidectin for demodicosis? In a European field study, fluralaner (oral or topical) achieved 98.0% mite-free rates versus 87.5% for imidacloprid/moxidectin, which failed the 90% efficacy threshold.[1] A controlled laboratory study found fluralaner reached 100% efficacy by Day 84 versus 0% for imidacloprid/moxidectin.[2]

How many doses of fluralaner are needed for generalized demodicosis? Both pivotal demodicosis studies used a single administration. The Petersen 2020 multicenter field study met the 90% efficacy threshold with one dose of either oral or topical fluralaner given on Day 0.[1]

Can a single dose of fluralaner cure canine sarcoptic mange? In a 2026 randomized, double-blind study, a fluralaner-based tablet reduced Sarcoptes scabiei counts significantly from Day 14 (p = 0.022) and reached 100% efficacy by Day 28 without retreatment, while the sarolaner control required retreatment to reach 100% by Day 44.[3]

Is there an oral combination alternative for canine scabies? Yes. A 2026 blinded, negative-controlled field study of 20 dogs found an oral afoxolaner-moxidectin-pyrantel combination reduced mite infestations by 97% after the first treatment and eliminated them (100%) after the second (p < 0.0005), with full resolution of pruritus, papules, and crusts and hair regrowth by Day 56; all untreated controls stayed infested.[5]

What are the safety risks of isoxazolines in dogs, and who is at highest risk? Isoxazolines carry an FDA label warning for neurologic adverse reactions (tremors, ataxia, seizures). 2025–2026 reviews reaffirm wide safety margins but a rare, sometimes serious neurologic signal concentrated in dogs with impaired drug efflux such as ABCB1/MDR1 variants or P-glycoprotein inhibition; take a medication and breed history and use caution in dogs with a prior seizure history.[6]

Does fluralaner work for both juvenile-onset and adult-onset demodicosis? The Petersen 2020 field study reported 96.0–100% mite-free rates across juvenile- and adult-onset subtypes for both fluralaner formulations, suggesting meaningful efficacy in both — though adult-onset disease still warrants a workup for underlying immunosuppression.[1]

Does fluralaner prevent tick-borne or vector-borne disease? No. A 2025 PRISMA systematic review confirmed broad acaricidal efficacy but found fluralaner does not prevent bites from blood-sucking ectoparasites and cannot prevent blood-borne pathogen transfer, because it kills after attachment rather than repelling.[7]

Changelog

• 2026-06-08: First published (fluralaner for generalized demodicosis; Petersen 2020, Fourie 2019).
• 2026-07-06: Consolidated four dated dispatch updates into this evergreen hub — added single-dose fluralaner vs. sarolaner for sarcoptic/otodectic mange (Cruz 2026), oral afoxolaner-moxidectin-pyrantel for scabies (Antoine 2026), the isoxazoline neurologic-safety / ABCB1-MDR1 reviews (Markowska-Buńka 2026; Jiang & Old 2025), the fluralaner PRISMA systematic review and non-repellent limit (Jiang & Old 2025), the canine-scabies critically appraised topic (Dumitrache & Cadiergues 2023), and the owner-reported isoxazoline safety survey (Palmieri 2020). Reorganized evidence by clinical question and added Comparators, Multimodal, and Practical decision support sections.